[Individualizing treatment of refractory and relapsed ITP in adults and its development of study].
Idiopathic thrombocytopenic purpura (ITP) is a common hematological disease. It bleeds with peripheral blood platelet reduction as the main clinical manifestation, and manifests a chronic history in adult people. 11% - 35% ITP patients develop into a refractory course, which may be related with gene polymorphisms. There is currently no consensus on how best to manage refractory/relapsed ITP. In part, this reflects the need for individualized treatment due to the patients' requirements and their responsiveness to therapies. The objective of this review is to provide a clinically useful guide to current management strategies. This article summarizes all the treatment for refractory ITP, and highlights new therapies, including the anti-CD20 antibody, thrombopoietic agents, TPO receptor agonist and HSCT. The pancytoprotector shows good effect in the treatment of refractory and relapsed ITP in China. In a word, to give different treatments individually is most important.
Huang
Yu
Y
Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing 100853, China; Tumor Center of the First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Li
Wei
W
Yang
Bo
B
Zhu
Hong-Li
HL
Dang
Yan-Hui
YH
D000328:Adult; D006801:Humans; D057285:Precision Medicine / Q000379:methods*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000628:therapy*; D012008:Recurrence